Metagenomi Q2 net loss widens to $27.5 million as collaboration revenue turns negative
Metagenomi reported second quarter 2026 results with a net loss of $27.5 million, or $0.73 per share, up from $19.9 million, or $0.54 per share, a year earlier. Collaboration revenue was negative $257 thousand, compared with $8.5 million in the second quarter of 2025, and the company ended the quarter with $120.7 million in cash and marketable securities, with runway anticipated through 4Q 2027. The company said it remains on track to submit an IND application for MGX-001 in hemophilia A in the fourth quarter of 2026.
Key points
- Net loss was $27.5 million, or $0.73 per share, versus $19.9 million, or $0.54 per share, in Q2 2025.
- Collaboration revenue was negative $257 thousand, compared with $8.5 million in Q2 2025.
- R&D expenses were $22.5 million, flat year over year; G&A expenses fell to $6.0 million from $7.0 million.
- Cash, cash equivalents and marketable securities were $120.7 million as of June 30, 2026, with runway anticipated through 4Q 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.